Salix HIV diarrhea drug hit with 2nd delay
This article was originally published in Scrip
Executive Summary
Investors on 5 September didn't overreact, but certainly weren't happy, about the news that the US FDA was delaying for the second time its decision on whether it would approve Salix Pharmaceuticals' investigational therapy for non-infectious diarrhea in patients with HIV/AIDS treated with antiretroviral therapy, known as crofelemer.